All In Biotech

Drug Trial Radar · NCT05722262

Study to Demonstrate the Bioequivalence of Single Oral Administration of K-001 Relative to Single Oral Coadministration of Separate Tablets of K-877-ER and CSG452

A Randomized, Open-Label, Six-Sequence, Three-Period Crossover Study to Demonstrate the Bioequivalence of Single Oral Administration of K-001 Relative to Single Oral Coadministration of Separate Tablets of K-877-ER Plus CSG452 in Healthy Adult Volunteers, and to Characterize the Food Effect on the Pharmacokinetics of K-001

Last checked: Nov 19, 2026Latest source record: Jun 2, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

30

Actual

Start

Feb 24, 2023

Primary completion

Apr 1, 2023

Study completion Apr 5, 2023

Sponsor

Lead sponsor
Kowa Research Institute, Inc.Industry
Sponsor type
Industry
First posted
Feb 10, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Supportive care
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to demonstrate the bioequivalence of single oral administration of K-001 relative to single oral co-administration of separate tablets of K-877-ER and CSG452 in healthy adult volunteers, and to characterize the food effect on the Pharmacokinetics(PK) of K-001.

Conditions

  • Healthy

Interventions

  • K-001Drug

    K-877-ER and CSG452 combination tablet

  • K-877-ERDrug

    K-877-ER tablet

  • CSG452Drug

    CSG452 tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cmax of K-877 and CSG452Time frame: 1 hour before dosing and at multiple time points (up to 48 hours) post dose
  2. AUC0-t of K-877 and CSG452Time frame: 1 hour before dosing and at multiple time points (up to 48 hours) post dose
  3. AUC0-inf of K-877-and CSG452Time frame: 1 hour before dosing and at multiple time points (up to 48 hours) post dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • PPD - Austin Research Unit

    Austin, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.